<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03667807</url>
  </required_header>
  <id_info>
    <org_study_id>91717306</org_study_id>
    <nct_id>NCT03667807</nct_id>
  </id_info>
  <brief_title>TMS-induced Plasticity Improving Cognitive Control in OCD</brief_title>
  <acronym>TIPICCO</acronym>
  <official_title>Transcranial Magnetic Stimulation (TMS)-Induced Plasticity Improving Cognitive Control in Obsessive-compulsive Disorder (OCD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Repetitive transcranial magnetic stimulation (rTMS) has been shown in several previous
      clinical trials to be an effective treatment for obsessive-compulsive disorder (OCD).
      However, the neural working mechanisms of rTMS in OCD are unknown, and the optimal
      stimulation sites have not yet been established. Our study aims to compare the clinical and
      neurobiological effects of three different rTMS stimulation protocols in OCD patients. 8
      weeks of rTMS therapy will be delivered in combination with cognitive behavioural therapy.
      Multimodal neuroimaging will be carried out before and after treatment in order to
      demonstrate the neurobiological effects of the therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2019</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>task based functional magnetic resonance imaging (fMRI) blood oxygen level dependent (BOLD) response</measure>
    <time_frame>Baseline and 12 weeks (i.e. post-treatment)</time_frame>
    <description>Change in task based fMRI BOLD response following rTMS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Yale-Brown Obsessive Compulsive Scale (Y-BOCS)</measure>
    <time_frame>Baseline, 6 weeks, (i.e. during treatment), 12 weeks (i.e. post-treatment), 22 weeks (i.e. follow-up)</time_frame>
    <description>OCD symptom severity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Functional connectivity</measure>
    <time_frame>Baseline and 12 weeks (i.e. post-treatment)</time_frame>
    <description>Measured using resting state fMRI</description>
  </other_outcome>
  <other_outcome>
    <measure>Structural connectivity</measure>
    <time_frame>Baseline and 12 weeks (i.e. post-treatment)</time_frame>
    <description>Measured using diffusion tensor imaging (DTI) MRI</description>
  </other_outcome>
  <other_outcome>
    <measure>Cortical excitation and inhibition (Motor-evoked potential amplitude, TMS-evoked potential, short interval cortical inhibition, long interval cortical inhibition)</measure>
    <time_frame>Baseline, 6 weeks, (i.e. during treatment), 12 weeks (i.e. post-treatment), 22 weeks (i.e. follow-up)</time_frame>
    <description>Measured using single and double pulse TMS + electromyography (EMG) / electroencephalography (EEG)</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurotransmitter concentrations</measure>
    <time_frame>Baseline and 12 weeks (i.e. post-treatment)</time_frame>
    <description>Measured using magnetic resonance spectroscopy (MRS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Planning</measure>
    <time_frame>Baseline, 12 weeks (i.e. post-treatment)</time_frame>
    <description>Measured using Tower of London cognitive task</description>
  </other_outcome>
  <other_outcome>
    <measure>Response inhibition</measure>
    <time_frame>Baseline, 12 weeks (i.e. post-treatment)</time_frame>
    <description>Measured using the stop-signal cognitive task</description>
  </other_outcome>
  <other_outcome>
    <measure>Error processing</measure>
    <time_frame>Baseline, 6 weeks, (i.e. during treatment), 12 weeks (i.e. post-treatment), 22 weeks (i.e. follow-up)</time_frame>
    <description>Measured using the Flanker cognitive task</description>
  </other_outcome>
  <other_outcome>
    <measure>EEG measures</measure>
    <time_frame>Baseline, 6 weeks, (i.e. during treatment), 12 weeks (i.e. post-treatment), 22 weeks (i.e. follow-up)</time_frame>
    <description>Resting state EEG, EEG event related potentials measured during tasks (Error related negativity using Flanker task, Late Positive Potential during appraisal of emotional stimuli)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>rTMS condition 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>rTMS condition 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>rTMS condition 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Repetitive transcranial magnetic stimulation</intervention_name>
    <description>Non invasive brain stimulation</description>
    <arm_group_label>rTMS condition 1</arm_group_label>
    <arm_group_label>rTMS condition 2</arm_group_label>
    <arm_group_label>rTMS condition 3</arm_group_label>
    <other_name>rTMS, TMS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        OCD patients:

          -  Age between 18 and 65

          -  Primary DSM-5 diagnosis of OCD

          -  Moderate to severe OCD symptoms (expressed as a minimum score of 16 on the Yale -
             Brown Obsessive Compulsive Scale (YBOCS)

          -  Unmedicated or stable dose of medication for at least 12 weeks prior to randomisation
             - with no plans to change dose during the study period

          -  At least 1 previous attempt at cognitive behavioural therapy (CBT) in lifetime

          -  At least 1 previous attempt with serotonergic medication or strong preference for
             non-pharmacological treatment

          -  Capacity to provide informed consent

        Healthy controls (baseline measurements only):

          -  Age between 18 and 65

          -  Capacity to provide informed consent

        Exclusion Criteria:

        OCD patients:

          -  MRI exclusion criteria (metal in body, pregnancy)

          -  TMS exclusion criteria (metal in body, history of epilepsy)

          -  Schizophrenia, bipolar disorder, active suicidal ideation, use of antipsychotics
             within last 12 weeks

          -  previous experience with rTMS as treatment

        Healthy controls:

          -  Current Diagnostic and Statistical Manual (DSM)-5 diagnosis

          -  Personal history of DSM-5 diagnosis

          -  use of psychotropic medications within last 12 months

          -  1st degree family member with OCD

          -  MRI exclusion criteria (as above)

          -  TMS exclusion criteria (as above)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sophie Fitzsimmons</last_name>
    <phone>+31625694905</phone>
    <email>s.fitzsimmons@amsterdamumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amsterdam UMC, location VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081 HZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>O A van den Heuvel, psychiatrist</last_name>
      <phone>+31-20-4449615</phone>
      <email>oa.vandenheuvel@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>O A van den Heuvel, psychiatrist</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>S Fitzsimmons, MBBCh MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>O.A. van den Heuvel</investigator_full_name>
    <investigator_title>Professor of Neuropsychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

